Jens Vogel, PhD

Jens Vogel is the President and Chief Operating Officer at Mirai Bio. 

Jens has 25 years of leadership experience in all aspects of biopharmaceutical development, platform innovation and end-to-end technical operations, as well as in building and transforming successful biotech businesses. Under his leadership, his teams have filed over 70 Investigational New Drug applications (INDs), helped bring 10 biologics to market and established innovative platforms for new modalities, such as cell and gene therapies. 

As Global Head of Biotech at Bayer Pharmaceuticals, Jens was responsible for biotech development, strategy and technical operations over multiple sites globally, supporting a $4 billion commercial biologics portfolio and driving innovation in industrialization platforms. Before rejoining Bayer, Jens was President and CEO of Boehringer Ingelheim Fremont Inc., leading end-to-end development and manufacturing as well as building and leading a fast-growing CDMO business. In this role, Jens was a member of BI’s Global Biopharma Executive Committee, responsible for Technology and Innovation. 

Prior to his years at BI, Jens held various roles of increasing responsibility in Biologics R&D at Bayer in Berkeley. He holds a PhD in Biotechnology/Biochemical Engineering from University of Braunschweig, Germany, with his graduate studies performed at the German National Research Center of Biotechnology and the Michael Smith Lab, UBC Vancouver, Canada.